Abstract
Dysfunction in or lack of osteoclasts result in osteopetrosis, a group of rare but often severe, genetic disorders characterized by an increase in bone mass, skeletal malformations and bone marrow failure that may be fatal. Several of the underlying defects have lately been characterized in humans and in animal disease models. In humans, these defects often involve mutations in genes expressing proteins involved in the acidification of the osteoclast sub-cellular compartment, a process necessary for proper bone resorption. So far, the only cure for children with severe osteopetrosis is allogeneic hematopoietic stem cell transplantation (SCT). However, the characterization of the genetic defects opens up the possibility for gene replacement therapy as an alternative to SCT. Recently, gene therapy targeting hematopoietic stem cells (HSC) in a mouse model of infantile malignant osteopetrosis was shown to correct many aspects of the disease. Here we review important aspects of this group of diseases and discuss the prospects for development of gene therapy of osteopetrosis.
Keywords: Osteoclast, osteoblast, bone remodelling, viral vector, stem cell transplantation, hematopoietic stem cell, engraftment, oc/oc mouse
Current Gene Therapy
Title: Prospects for Gene Therapy of Osteopetrosis
Volume: 9 Issue: 3
Author(s): Maria Askmyr, Carmen Flores, Anders Fasth and Johan Richter
Affiliation:
Keywords: Osteoclast, osteoblast, bone remodelling, viral vector, stem cell transplantation, hematopoietic stem cell, engraftment, oc/oc mouse
Abstract: Dysfunction in or lack of osteoclasts result in osteopetrosis, a group of rare but often severe, genetic disorders characterized by an increase in bone mass, skeletal malformations and bone marrow failure that may be fatal. Several of the underlying defects have lately been characterized in humans and in animal disease models. In humans, these defects often involve mutations in genes expressing proteins involved in the acidification of the osteoclast sub-cellular compartment, a process necessary for proper bone resorption. So far, the only cure for children with severe osteopetrosis is allogeneic hematopoietic stem cell transplantation (SCT). However, the characterization of the genetic defects opens up the possibility for gene replacement therapy as an alternative to SCT. Recently, gene therapy targeting hematopoietic stem cells (HSC) in a mouse model of infantile malignant osteopetrosis was shown to correct many aspects of the disease. Here we review important aspects of this group of diseases and discuss the prospects for development of gene therapy of osteopetrosis.
Export Options
About this article
Cite this article as:
Askmyr Maria, Flores Carmen, Fasth Anders and Richter Johan, Prospects for Gene Therapy of Osteopetrosis, Current Gene Therapy 2009; 9 (3) . https://dx.doi.org/10.2174/156652309788488613
DOI https://dx.doi.org/10.2174/156652309788488613 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Efficacy and Cardiovascular Safety of Metformin
Current Drug Safety Primate-Accelerated Evolutionary Genes: Novel Routes to Drug Discovery in Psychiatric Disorders
Current Medicinal Chemistry Psychological Interventions for Parents of Children who have Cancer: A Meta-Analytic Review
Current Pediatric Reviews The Applications of Targeting Anti-Cancer Agents in Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Targeting the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cells
Current Medicinal Chemistry Gene Transfer for Inborn Errors of Metabolism of the Liver: The Clinical Perspective
Current Pharmaceutical Design Epigenetics: New Concepts of Old Phenomena in Vascular Physiology
Current Vascular Pharmacology Neuropharmacological Mechanisms Underlying the Neuroprotective Effects of Methylphenidate
Current Neuropharmacology Inhibition of Angiogenesis as a Treatment Strategy for Neuroblastoma
Current Cancer Therapy Reviews Autoimmune Hepatitis
Current Pediatric Reviews Recent Patents Reveal Microtubules as Persistent Promising Target for Novel Drug Development for Cancers
Recent Patents on Anti-Infective Drug Discovery Rediscovering Tocophersolan: A Renaissance for Nano-Based Drug Delivery and Nanotheranostic Applications
Current Drug Targets Ocular Toxicities in Cancer Therapy: Still Overlooked
Current Cancer Therapy Reviews The Synthesis and Evaluation of Novel Lactate Dehydrogenase Nanobioconjugates
Current Nanoscience Evolving Strategies for the Treatment of T-Cell Lymphoma: A Systematic Review and Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Epidermolysis Bullosa: The Pediatricians Role
Current Pediatric Reviews Antioxidant Food Supplements and Obesity-Related Inflammation
Current Medicinal Chemistry Genetic Enhancement in Sport: Just Another Form of Doping?
Recent Patents on DNA & Gene Sequences Oestrogen-A Protective Factor in Schizophrenia?
Current Psychiatry Reviews The Role of Folate-supplementation in Depression: A Narrative Review
Current Psychopharmacology